<DOC>
	<DOCNO>NCT00902681</DOCNO>
	<brief_summary>This bioequivalence ( BE ) study satisfy FDA regulatory requirement extend release drug product transfer Zwickau , Germany Vega Baja , Puerto-Rico .</brief_summary>
	<brief_title>A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets ( Toviazâ„¢ ) In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Healthy male and/or female subject Body Mass Index ( BMI ) 17.5 30.5 kg/m2 Subjects evidence history clinically significant urologic diseases A positive urine drug screen Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Bioequivalence , Pharmacokinetics</keyword>
</DOC>